Investigating how pancreatic cancer uses nutrients to survive

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial explores the metabolic pathways that pancreatic ductal adenocarcinoma (PDAC) relies on for survival. By administering uniformly-labeled [13C]glucose during surgery, researchers aim to trace the metabolic activity of pancreatic cancer cells compared to normal pancreatic cells. The study involves collecting biopsies from patients undergoing surgery to analyze the metabolic dependencies of the cancer using advanced liquid chromatography-mass spectrometry (LC-MS) techniques. The goal is to uncover new insights into how these tumors manage nutrients, which could inform future treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female patients \>= 18 years of age
* Pancreatic adenocarcinoma patients, previously diagnosed by biopsy, who are candidates for intended curative resection either with or without neoadjuvant chemotherapy
* Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed pancreatectomy
* 16 patients will be enrolled including 8 with no prior treatment and 8 treated with at least 3 months of neoadjuvant chemotherapy
* All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry

Exclusion Criteria:

* Patients receiving any anti-cancer therapy (chemotherapy, immunotherapy, and/or biologic therapy) for 8 patients; the other 8 patients will be treated with neoadjuvant chemotherapy but no radiation, biologic or immunotherapy prior to surgery
* Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
* Concomitant active malignancy
* Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)

Where it's running

• Cooperman Barnabas Medical Center (Saint Barnabas Medical Center)
  Livingston, New Jersey, United States Recruiting
• Rutgers Cancer Institute of New Jersey
  New Brunswick, New Jersey, United States Recruiting

Study contacts

• Principal investigator: Howard S Hochster, MD — Rutgers Cancer Institute of New Jersey
• Study coordinator: Howard Hochster, MD
• Email: howard.hochster@rutgers.edu
• Phone: 732-235-5912

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Telisotuzumab Adizutecan with Gemcitabine and Nab-Paclitaxel in Pancreatobiliary Cancers

  This study tests whether adding telisotuzumab adizutecan to standard chemotherapy can help adults with pancreatobiliary cancers see a benefit.

  Recruiting at 7 sites Phase 2 AbbVie · Hattiesburg, Mississippi and 6 other locations · NCT07769502

• GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC

  This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.

  Recruiting at 10 sites Phase 1/2 Genfleet Therapeutics (Shanghai) Inc. · Concord, New South Wales and 16 other locations · NCT07678593

• First-in-human test of BLU-924 for KRAS-mutant advanced cancers

  This trial tests BLU-924 in adults with KRAS-mutant advanced solid tumors, including PDAC, NSCLC, and CRC, to see if it is safe and may help control cancer.

  Recruiting at 3 sites Phase 1/2 Blueprint Medicines Corporation · Sarasota, Florida and 15 other locations · NCT07629960

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.